Chia-Tai Tiangqing Files IND for Biotech Product Licensed from Alphamab

Chia-Tai Tiangqing Pharma Group (CTTQ), a diversified China drug company headquartered in Jiangsu province, filed an IND with the CFDA to begin clinical trials of its Recombinant Human Coagulation Factor VIII (rhFVIII). CTTQ in-licensed rights to the product from Alphamab, a biotech located in Suzhou’s BioBay Park. The two companies have been collaborating on developing the product since 2010. More details.... Share this with colleagues: // //